Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 7/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.55 |
| ▸ | GFRA3 | O60609 | 1/20 | 0.50 |
| ▸ | RET | P07949 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 2/20 | 0.48 |
| ▸ | KDM1A | O60341 | 2/20 | 0.45 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.37 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1745527 | 0.85 | SRD5A1 (0.45) | CYP17A1CYP3A4CYP11B2CYP11B1GFRA3 | |
| SCHEMBL16363081 | 0.85 | SRD5A1 (0.45) | CYP17A1CYP3A4CYP11B2CYP11B1GFRA3 | |
| SCHEMBL16363092 | 0.85 | SRD5A1 (0.45) | CYP17A1CYP3A4CYP11B2CYP11B1GFRA3 | |
| SCHEMBL1744877 | 0.84 | GFRA3 (0.62) | CYP17A1CYP3A4CYP11B2CYP11B1GFRA3 | |
| SCHEMBL19116602 | 0.84 | GFRA3 (0.51) | CYP17A1CYP3A4CYP11B2CYP11B1GFRA3 | |
| SCHEMBL1745279 | 0.83 | GFRA3 (0.50) | CYP17A1CYP3A4CYP11B2CYP11B1GFRA3 | |
| SCHEMBL1745326 | 0.83 | PGR (0.51) | CYP17A1CYP3A4CYP11B2CYP11B1GFRA3 | |
| SCHEMBL28755063 | 0.80 | GFRA3 (0.48) | CYP17A1CYP3A4CYP11B2CYP11B1GFRA3 | |
| SCHEMBL1744785 | 0.79 | PGR (0.48) | CYP3A4GFRA3RETPGRKDM1A | |
| SCHEMBL5439689 | 0.79 | PGR (0.61) | CYP11B2CYP11B1GFRA3RETPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1559422-B1 | RECEPTOR FUNCTION CONTROLLING AGENT | TAKEDA PHARMACEUTICAL (JP) | 2014-04-30 | — | — | EP | disclosed |
| EP-2385032-A1 | GPR40 Receptor function regulator | Takeda Pharmaceutical Company Limited (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-7960369-B2 | Receptor function regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20090012093-A1 | Receptor Function Regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| CN-1735408-A | Receptor function controlling agent | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-02-15 | — | — | CN | disclosed |
| EP-1559422-A1 | RECEPTOR FUNCTION CONTROLLING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012093-A1 | Receptor Function Regulator | GPR119, GIPR, INSR | CYP17A1 2361/4885CYP3A4 3431/4885CYP11B2 2975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.